Composition comprising UNE-L domain of leucyl-tRNA synthetase as effective ingredient for augmenting muscle
AssigneesGachon University of Industry-Academic Cooperation Foundation, Gil Medical Center
InventorsMee Sup Yoon, Jie Chen, Kook Son, Cheol Soo Choi, Sunghoon Kim, Jung Min Han
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition comprising the UNE-L domain of leucyl-tRNA synthetase as an effective ingredient for increasing muscle. More particularly, the UNE-L domain of LRS according to the present invention, which is a region that controls activity of Vps34, activates mTORC1 involved in protein synthesis and increases myocyte differentiation and muscle fiber regeneration, thus finding useful application in muscle augmentation.
Claims6
A method for increasing muscle, comprising administering a pharmaceutically effective dose of the UNE-L domain amino acid sequence of leucyl-tRNA synthetase (LRS) according to SEQ. ID. NO:1 or a polynucleotide encoding the same to a subject.
A method for preventing or treating muscle disease, comprising administering a pharmaceutically effective dose of the UNE-L domain amino acid sequence of leucyl-tRNA synthetase (LRS) according to SEQ. ID. NO:1 or a polynucleotide encoding the same to a subject.
A screening method of a candidate substance for the prevention or treatment of muscle disease, comprising the following steps:
- 1) applying the UNE-L domain of leucyl-tRNA synthetase C-terminus (SEQ:
- ID:
- 1) and a test sample to cells expressing Vps34 (vacuolar protein sorting 34) protein;
- 2) culturing the cells of step 1);
- and
- 3) selecting a test sample that increases the activity of phospholipase D1 (PLD1) or S6 kinase 1 (S6K1) in the culture medium of step 2) by comparing the activity of those in the control group not-treated with the UNE-L domain.
Dependencies are inferred from the claim text.